Christian attained his medical degree at the University of Göttingen, Germany. He has a long-standing interest in functional genomics and in deciphering the systematic rewiring of cancer transcriptomes. After he completed his postdoctoral training with Michael Hemann at MIT in the US, he returned to Germany to start his own lab at LMU Munich’s University Hospital in 2017. Since 2019, his lab has been funded by the Max Eder Program — a set up grant awarded by German Cancer Aid. Christian is driven by the idea of molecular target discovery for cancer therapy and the translation of his findings into clinical applications. This passion is reinforced on a daily basis through his work as a senior resident physician in pediatrics, where he treats children suffering from devastating diseases.

Martin studied biotechnology in Braunschweig, Germany and cell and molecular biology in Rhode Island, USA. He subsequently obtained a PhD in Immunology from the Max Planck Institute of Immunology and Epigenetics in Freiburg, Germany. After successful completion of his PhD, Martin moved to Munich, Germany, joining the Helmholtz Zentrum to work on the establishment of a CRISPR/Cas9 screening pipeline in patient-derived xenograft models of acute leukemias. Within this project, Martin and Christian joined forces and established a multiplex cloning protocol for custom sgRNA libraries named CLUE. In 2020, Martin was recruited by AVA LifeScience to lead their R&D team, developing novel standards for FACS-based diagnostics.